Please assess the completion status of the following clinical trial:

Trial Title: Oxaliplatin, Gemcitabine, and Erlotinib Study in Patients With Advanced Chemo-naïve Pancreatic Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patient's age between 18 and 75 years.~2. Presence of microscopic diagnosis of pancreatic cancer.~3. The disease is Locally advanced deemed by the surgeon to be unresectable, or metastatic disease.~4. Karnofsky Performance status \>50%.~5. Prior radiotherapy for local diseases is allowed provided disease progression had been documented, and treatment completed at least 4 weeks before random assignment~6. Prior chemotherapy is not permitted, except for fluorouracil given concurrently as a radiosensitizer.~7. Patients must have normal organ function evidenced by~   * Cr \<1.5 ULN~  * ANC \>1000~  * platelets\> 100,000~  * total bilirubin \<1.5ULN.~8. Pain should be controlled for at least two weeks without an increase in the narcotic consumption.~9. Biliary obstruction should be controlled for at least two weeks evident by stable or improving liver function tests especially total bilirubin.~10. Patient has signed a Patient Informed Consent Form.~11. For all females of childbearing potential, a negative pregnancy test must be obtained within 72 hours before starting therapy.~Exclusion Criteria:~1. Contraindication to chemotherapy.~2. Evidence of uncontrolled CNS disease (patients with controlled CNS disease for 4 weeks using the same imaging method and for whom are off steroid will be eligible)~3. Uncontrolled Nausea and Vomiting~4. Diagnosis of other malignancy in the last 5 years excluding non-melanoma skin cancer and in -situ cervical cancer.~5. Subjects unlikely to comply with protocol, e.g. uncooperative attitude, inability to return for follow- up visits and unlikelihood of completing the study.~6. Any known history of hypersensitivity to the study drugs.~7. Pregnant or lactating women.~8. Participation in a clinical trial with any investigational drug used with curative intent and within 30 days prior to study entry~9. Peripheral sensitive neuropathy with functional impairment prior to study entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).